APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Transmucosal Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oral Transmucosal Drugs Industry Research Report 2026

1 January 2026137 pages

Choose your research edition.

Industry ResearchOral Transmucosal Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Transmucosal Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Oral Transmucosal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Transmucosal Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Transmucosal Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Oral Transmucosal Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Oral Transmucosal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Oral Transmucosal Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Oral Transmucosal Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Oral Transmucosal Drugs include Access Pharmaceutical Inc., Aquestive Therapeutics, Inc., Bristol-Myers Squibb Company, C.L Pharm, Cure Pharmaceutical, Eisai Co., Ltd., IntelGenx Corp., LTS Lohmann Therapie-Systeme AG and NAL Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Oral Transmucosal Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oral Transmucosal Drugs Market by Company

Access Pharmaceutical Inc.

Aquestive Therapeutics, Inc.

Bristol-Myers Squibb Company

C.L Pharm

Cure Pharmaceutical

Eisai Co., Ltd.

IntelGenx Corp.

LTS Lohmann Therapie-Systeme AG

NAL Pharma

Otsuka Pharmaceutical Co., Ltd.

Soligenix

Viatris

ZIM Laboratories Limited

GlaxoSmithKline plc

Teva Pharmaceutical Industries Ltd.

Oral Transmucosal Drugs Segment by Type

Liquid Spray

Tablets

Gels

Films

Others

Oral Transmucosal Drugs Segment by Application

Cardiovascular Disorders

Diabetes

Acute Pain Managements

Others

Oral Transmucosal Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Transmucosal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Transmucosal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Transmucosal Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Oral Transmucosal Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Oral Transmucosal Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Oral Transmucosal Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oral Transmucosal Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Oral Transmucosal Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Oral Transmucosal Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Oral Transmucosal Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Oral Transmucosal Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Oral Transmucosal Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Oral Transmucosal Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Oral Transmucosal Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Oral Transmucosal Drugs, Product Type & Application Table 14. Global Oral Transmucosal Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Oral Transmucosal Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Access Pharmaceutical Inc. Company Information Table 19. Access Pharmaceutical Inc. Business Overview Table 20. Access Pharmaceutical Inc. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Access Pharmaceutical Inc. Oral Transmucosal Drugs Product Portfolio Table 22. Access Pharmaceutical Inc. Recent Developments Table 23. Aquestive Therapeutics, Inc. Company Information Table 24. Aquestive Therapeutics, Inc. Business Overview Table 25. Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Product Portfolio Table 27. Aquestive Therapeutics, Inc. Recent Developments Table 28. Bristol-Myers Squibb Company Company Information Table 29. Bristol-Myers Squibb Company Business Overview Table 30. Bristol-Myers Squibb Company Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Bristol-Myers Squibb Company Oral Transmucosal Drugs Product Portfolio Table 32. Bristol-Myers Squibb Company Recent Developments Table 33. C.L Pharm Company Information Table 34. C.L Pharm Business Overview Table 35. C.L Pharm Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. C.L Pharm Oral Transmucosal Drugs Product Portfolio Table 37. C.L Pharm Recent Developments Table 38. Cure Pharmaceutical Company Information Table 39. Cure Pharmaceutical Business Overview Table 40. Cure Pharmaceutical Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Cure Pharmaceutical Oral Transmucosal Drugs Product Portfolio Table 42. Cure Pharmaceutical Recent Developments Table 43. Eisai Co., Ltd. Company Information Table 44. Eisai Co., Ltd. Business Overview Table 45. Eisai Co., Ltd. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Eisai Co., Ltd. Oral Transmucosal Drugs Product Portfolio Table 47. Eisai Co., Ltd. Recent Developments Table 48. IntelGenx Corp. Company Information Table 49. IntelGenx Corp. Business Overview Table 50. IntelGenx Corp. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. IntelGenx Corp. Oral Transmucosal Drugs Product Portfolio Table 52. IntelGenx Corp. Recent Developments Table 53. LTS Lohmann Therapie-Systeme AG Company Information Table 54. LTS Lohmann Therapie-Systeme AG Business Overview Table 55. LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Product Portfolio Table 57. LTS Lohmann Therapie-Systeme AG Recent Developments Table 58. NAL Pharma Company Information Table 59. NAL Pharma Business Overview Table 60. NAL Pharma Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. NAL Pharma Oral Transmucosal Drugs Product Portfolio Table 62. NAL Pharma Recent Developments Table 63. Otsuka Pharmaceutical Co., Ltd. Company Information Table 64. Otsuka Pharmaceutical Co., Ltd. Business Overview Table 65. Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Product Portfolio Table 67. Otsuka Pharmaceutical Co., Ltd. Recent Developments Table 68. Soligenix Company Information Table 69. Soligenix Business Overview Table 70. Soligenix Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Soligenix Oral Transmucosal Drugs Product Portfolio Table 72. Soligenix Recent Developments Table 73. Viatris Company Information Table 74. Viatris Business Overview Table 75. Viatris Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Viatris Oral Transmucosal Drugs Product Portfolio Table 77. Viatris Recent Developments Table 78. ZIM Laboratories Limited Company Information Table 79. ZIM Laboratories Limited Business Overview Table 80. ZIM Laboratories Limited Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. ZIM Laboratories Limited Oral Transmucosal Drugs Product Portfolio Table 82. ZIM Laboratories Limited Recent Developments Table 83. GlaxoSmithKline plc Company Information Table 84. GlaxoSmithKline plc Business Overview Table 85. GlaxoSmithKline plc Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline plc Oral Transmucosal Drugs Product Portfolio Table 87. GlaxoSmithKline plc Recent Developments Table 88. Teva Pharmaceutical Industries Ltd. Company Information Table 89. Teva Pharmaceutical Industries Ltd. Business Overview Table 90. Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Product Portfolio Table 92. Teva Pharmaceutical Industries Ltd. Recent Developments Table 93. Global Oral Transmucosal Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Oral Transmucosal Drugs Sales by Region (2021-2026) & (K Units) Table 95. Global Oral Transmucosal Drugs Sales Market Share by Region (2021-2026) Table 96. Global Oral Transmucosal Drugs Sales by Region (2027-2032) & (K Units) Table 97. Global Oral Transmucosal Drugs Sales Market Share by Region (2027-2032) Table 98. Global Oral Transmucosal Drugs Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Oral Transmucosal Drugs Revenue Market Share by Region (2021-2026) Table 100. Global Oral Transmucosal Drugs Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Oral Transmucosal Drugs Revenue Market Share by Region (2027-2032) Table 102. North America Oral Transmucosal Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 104. North America Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 105. North America Oral Transmucosal Drugs Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Oral Transmucosal Drugs Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Oral Transmucosal Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 109. Europe Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 110. Europe Oral Transmucosal Drugs Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Oral Transmucosal Drugs Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Oral Transmucosal Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Oral Transmucosal Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Oral Transmucosal Drugs Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Oral Transmucosal Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 119. South America Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 120. South America Oral Transmucosal Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Oral Transmucosal Drugs Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Oral Transmucosal Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Oral Transmucosal Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Oral Transmucosal Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Oral Transmucosal Drugs Sales by Type (2021-2026) & (K Units) Table 128. Global Oral Transmucosal Drugs Sales by Type (2027-2032) & (K Units) Table 129. Global Oral Transmucosal Drugs Sales Market Share by Type (2021-2026) Table 130. Global Oral Transmucosal Drugs Sales Market Share by Type (2027-2032) Table 131. Global Oral Transmucosal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Oral Transmucosal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Oral Transmucosal Drugs Revenue Market Share by Type (2021-2026) Table 134. Global Oral Transmucosal Drugs Revenue Market Share by Type (2027-2032) Table 135. Global Oral Transmucosal Drugs Price by Type (2021-2026) & (US$/Unit) Table 136. Global Oral Transmucosal Drugs Price by Type (2027-2032) & (US$/Unit) Table 137. Global Oral Transmucosal Drugs Sales by Application (2021-2026) & (K Units) Table 138. Global Oral Transmucosal Drugs Sales by Application (2027-2032) & (K Units) Table 139. Global Oral Transmucosal Drugs Sales Market Share by Application (2021-2026) Table 140. Global Oral Transmucosal Drugs Sales Market Share by Application (2027-2032) Table 141. Global Oral Transmucosal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Oral Transmucosal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Oral Transmucosal Drugs Revenue Market Share by Application (2021-2026) Table 144. Global Oral Transmucosal Drugs Revenue Market Share by Application (2027-2032) Table 145. Global Oral Transmucosal Drugs Price by Application (2021-2026) & (US$/Unit) Table 146. Global Oral Transmucosal Drugs Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Oral Transmucosal Drugs Distributors List Table 150. Oral Transmucosal Drugs Customers List Table 151. Oral Transmucosal Drugs Industry Trends Table 152. Oral Transmucosal Drugs Industry Drivers Table 153. Oral Transmucosal Drugs Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oral Transmucosal Drugs Product Image Figure 5. Global Oral Transmucosal Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Oral Transmucosal Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Oral Transmucosal Drugs Sales (2021-2032) & (K Units) Figure 8. Global Oral Transmucosal Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Liquid Spray Product Image Figure 10. Tablets Product Image Figure 11. Gels Product Image Figure 12. Films Product Image Figure 13. Others Product Image Figure 14. Cardiovascular Disorders Product Image Figure 15. Diabetes Product Image Figure 16. Acute Pain Managements Product Image Figure 17. Others Product Image Figure 18. Global Oral Transmucosal Drugs Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Oral Transmucosal Drugs, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Oral Transmucosal Drugs Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Oral Transmucosal Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Oral Transmucosal Drugs Sales by Region in 2025 Figure 24. Global Oral Transmucosal Drugs Revenue by Region in 2025 Figure 25. North America Oral Transmucosal Drugs Market Size by Country in 2025 Figure 26. North America Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 27. North America Oral Transmucosal Drugs Revenue Market Share by Country (2021-2032) Figure 28. United States Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Oral Transmucosal Drugs Market Size by Country in 2025 Figure 31. Europe Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 32. Europe Oral Transmucosal Drugs Revenue Market Share by Country (2021-2032) Figure 33. Germany Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Asia Pacific Oral Transmucosal Drugs Market Size by Country in 2025 Figure 39. Asia Pacific Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 40. Asia Pacific Oral Transmucosal Drugs Revenue Market Share by Country (2021-2032) Figure 41. China Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Japan Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. South Korea Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. India Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Australia Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. China Taiwan Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South America Oral Transmucosal Drugs Market Size by Country in 2025 Figure 50. South America Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 51. South America Oral Transmucosal Drugs Revenue Market Share by Country (2021-2032) Figure 52. Mexico Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Brazil Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Middle East and Africa Oral Transmucosal Drugs Market Size by Country in 2025 Figure 56. Middle East and Africa Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 57. Middle East and Africa Oral Transmucosal Drugs Revenue Market Share by Country (2021-2032) Figure 58. Turkey Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. UAE Oral Transmucosal Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Global Oral Transmucosal Drugs Sales Market Share by Type (2021-2032) Figure 62. Global Oral Transmucosal Drugs Revenue Market Share by Type (2021-2032) Figure 63. Global Oral Transmucosal Drugs Price (US$/Unit) by Type (2021-2032) Figure 64. Global Oral Transmucosal Drugs Sales Market Share by Application (2021-2032) Figure 65. Global Oral Transmucosal Drugs Revenue Market Share by Application (2021-2032) Figure 66. Global Oral Transmucosal Drugs Price (US$/Unit) by Application (2021-2032) Figure 67. Oral Transmucosal Drugs Value Chain Figure 68. Oral Transmucosal Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Oral Transmucosal Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Liquid Spray
  • Tablets
  • Gels
  • Films
  • Others
Applications
  • Cardiovascular Disorders
  • Diabetes
  • Acute Pain Managements
  • Others
Companies covered
  • Access Pharmaceutical Inc.
  • Aquestive Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • C.L Pharm
  • Cure Pharmaceutical
  • Eisai Co., Ltd.
  • IntelGenx Corp.
  • LTS Lohmann Therapie-Systeme AG
  • NAL Pharma
  • Otsuka Pharmaceutical Co., Ltd.
  • Soligenix
  • Viatris
  • ZIM Laboratories Limited
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Oral Transmucosal Drugs Market Size (2021-2032)
  4. 2.2.2 Global Oral Transmucosal Drugs Sales (2021-2032)
  5. 2.2.3 Global Oral Transmucosal Drugs Market Average Price (2021-2032)
  6. 2.3 Oral Transmucosal Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Liquid Spray
  9. 2.3.3 Tablets
  10. 2.3.4 Gels
  11. 2.3.5 Films
  12. 2.3.6 Others
  13. 2.4 Oral Transmucosal Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Cardiovascular Disorders
  16. 2.4.3 Diabetes
  17. 2.4.4 Acute Pain Managements
  18. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Oral Transmucosal Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Oral Transmucosal Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Oral Transmucosal Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Oral Transmucosal Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Oral Transmucosal Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Oral Transmucosal Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Oral Transmucosal Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Oral Transmucosal Drugs, Established Date
  9. 3.9 Global Oral Transmucosal Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Access Pharmaceutical Inc.
  2. 4.1.1 Access Pharmaceutical Inc. Company Information
  3. 4.1.2 Access Pharmaceutical Inc. Business Overview
  4. 4.1.3 Access Pharmaceutical Inc. Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Access Pharmaceutical Inc. Oral Transmucosal Drugs Product Portfolio
  6. 4.1.5 Access Pharmaceutical Inc. Recent Developments
  7. 4.2 Aquestive Therapeutics, Inc.
  8. 4.2.1 Aquestive Therapeutics, Inc. Company Information
  9. 4.2.2 Aquestive Therapeutics, Inc. Business Overview
  10. 4.2.3 Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Product Portfolio
  12. 4.2.5 Aquestive Therapeutics, Inc. Recent Developments
  13. 4.3 Bristol-Myers Squibb Company
  14. 4.3.1 Bristol-Myers Squibb Company Company Information
  15. 4.3.2 Bristol-Myers Squibb Company Business Overview
  16. 4.3.3 Bristol-Myers Squibb Company Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Bristol-Myers Squibb Company Oral Transmucosal Drugs Product Portfolio
  18. 4.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 4.4 C.L Pharm
  20. 4.4.1 C.L Pharm Company Information
  21. 4.4.2 C.L Pharm Business Overview
  22. 4.4.3 C.L Pharm Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 C.L Pharm Oral Transmucosal Drugs Product Portfolio
  24. 4.4.5 C.L Pharm Recent Developments
  25. 4.5 Cure Pharmaceutical
  26. 4.5.1 Cure Pharmaceutical Company Information
  27. 4.5.2 Cure Pharmaceutical Business Overview
  28. 4.5.3 Cure Pharmaceutical Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Cure Pharmaceutical Oral Transmucosal Drugs Product Portfolio
  30. 4.5.5 Cure Pharmaceutical Recent Developments
  31. 4.6 Eisai Co., Ltd.
  32. 4.6.1 Eisai Co., Ltd. Company Information
  33. 4.6.2 Eisai Co., Ltd. Business Overview
  34. 4.6.3 Eisai Co., Ltd. Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Eisai Co., Ltd. Oral Transmucosal Drugs Product Portfolio
  36. 4.6.5 Eisai Co., Ltd. Recent Developments
  37. 4.7 IntelGenx Corp.
  38. 4.7.1 IntelGenx Corp. Company Information
  39. 4.7.2 IntelGenx Corp. Business Overview
  40. 4.7.3 IntelGenx Corp. Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 IntelGenx Corp. Oral Transmucosal Drugs Product Portfolio
  42. 4.7.5 IntelGenx Corp. Recent Developments
  43. 4.8 LTS Lohmann Therapie-Systeme AG
  44. 4.8.1 LTS Lohmann Therapie-Systeme AG Company Information
  45. 4.8.2 LTS Lohmann Therapie-Systeme AG Business Overview
  46. 4.8.3 LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Product Portfolio
  48. 4.8.5 LTS Lohmann Therapie-Systeme AG Recent Developments
  49. 4.9 NAL Pharma
  50. 4.9.1 NAL Pharma Company Information
  51. 4.9.2 NAL Pharma Business Overview
  52. 4.9.3 NAL Pharma Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 NAL Pharma Oral Transmucosal Drugs Product Portfolio
  54. 4.9.5 NAL Pharma Recent Developments
  55. 4.10 Otsuka Pharmaceutical Co., Ltd.
  56. 4.10.1 Otsuka Pharmaceutical Co., Ltd. Company Information
  57. 4.10.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
  58. 4.10.3 Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Product Portfolio
  60. 4.10.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
  61. 4.11 Soligenix
  62. 4.11.1 Soligenix Company Information
  63. 4.11.2 Soligenix Business Overview
  64. 4.11.3 Soligenix Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Soligenix Oral Transmucosal Drugs Product Portfolio
  66. 4.11.5 Soligenix Recent Developments
  67. 4.12 Viatris
  68. 4.12.1 Viatris Company Information
  69. 4.12.2 Viatris Business Overview
  70. 4.12.3 Viatris Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Viatris Oral Transmucosal Drugs Product Portfolio
  72. 4.12.5 Viatris Recent Developments
  73. 4.13 ZIM Laboratories Limited
  74. 4.13.1 ZIM Laboratories Limited Company Information
  75. 4.13.2 ZIM Laboratories Limited Business Overview
  76. 4.13.3 ZIM Laboratories Limited Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 ZIM Laboratories Limited Oral Transmucosal Drugs Product Portfolio
  78. 4.13.5 ZIM Laboratories Limited Recent Developments
  79. 4.14 GlaxoSmithKline plc
  80. 4.14.1 GlaxoSmithKline plc Company Information
  81. 4.14.2 GlaxoSmithKline plc Business Overview
  82. 4.14.3 GlaxoSmithKline plc Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 GlaxoSmithKline plc Oral Transmucosal Drugs Product Portfolio
  84. 4.14.5 GlaxoSmithKline plc Recent Developments
  85. 4.15 Teva Pharmaceutical Industries Ltd.
  86. 4.15.1 Teva Pharmaceutical Industries Ltd. Company Information
  87. 4.15.2 Teva Pharmaceutical Industries Ltd. Business Overview
  88. 4.15.3 Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Product Portfolio
  90. 4.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments
5 Global Oral Transmucosal Drugs Market Scenario by Region
  1. 5.1 Global Oral Transmucosal Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Oral Transmucosal Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Oral Transmucosal Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Oral Transmucosal Drugs Sales by Region: 2027-2032
  5. 5.3 Global Oral Transmucosal Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Oral Transmucosal Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Oral Transmucosal Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Oral Transmucosal Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Oral Transmucosal Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Oral Transmucosal Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Oral Transmucosal Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Oral Transmucosal Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Oral Transmucosal Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Oral Transmucosal Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Oral Transmucosal Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Oral Transmucosal Drugs Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Oral Transmucosal Drugs Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Oral Transmucosal Drugs Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Oral Transmucosal Drugs Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Oral Transmucosal Drugs Market Facts & Figures by Country
  35. 5.7.1 South America Oral Transmucosal Drugs Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Oral Transmucosal Drugs Sales by Country (2021-2032)
  37. 5.7.3 South America Oral Transmucosal Drugs Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Oral Transmucosal Drugs Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Oral Transmucosal Drugs Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Oral Transmucosal Drugs Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Oral Transmucosal Drugs Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Oral Transmucosal Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Oral Transmucosal Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Oral Transmucosal Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Oral Transmucosal Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Oral Transmucosal Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Oral Transmucosal Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Oral Transmucosal Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Oral Transmucosal Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Oral Transmucosal Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Oral Transmucosal Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Oral Transmucosal Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Oral Transmucosal Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Oral Transmucosal Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Oral Transmucosal Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Oral Transmucosal Drugs Value Chain Analysis
  2. 8.1.1 Oral Transmucosal Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Oral Transmucosal Drugs Production Mode & Process
  5. 8.2 Oral Transmucosal Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Oral Transmucosal Drugs Distributors
  8. 8.2.3 Oral Transmucosal Drugs Customers
9 Global Oral Transmucosal Drugs Analyzing Market Dynamics
  1. 9.1 Oral Transmucosal Drugs Industry Trends
  2. 9.2 Oral Transmucosal Drugs Industry Drivers
  3. 9.3 Oral Transmucosal Drugs Industry Opportunities and Challenges
  4. 9.4 Oral Transmucosal Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst